Press Releases

Eutopos Pharma Selected to Join Quest for Health as Vidac Pharma Group Expands European Operations

Selection supports the establishment of Eutopos Pharma and the Group's growth in Europe's biotech ecosystem. London, UK, 15 July 2026 – Vidac Pharma Holdings Plc. announces that its planned French affiliate, Eutopos Pharma, has been selected to join Quest for Health.

Vidac Pharma Announces Completion of Patient Enrollment in Phase 2B Study of VDA-1102 for High-Risk Actinic Keratosis

All 39 patients enrolled; follow-up continues as planned. London, UK, 12 June 2026 – Vidac Pharma Holdings Plc. (XETRA: T9G | ISIN: GB00BM9XQ619 | WKN: A3DTUQ) announces the completion of patient enrollment in the Company's Phase 2B clinical study evaluating VDA-1102.

Vidac Pharma Receives Notice of Allowance for Canadian Patent Covering Proprietary Oncology Platform

Strengthens global intellectual property portfolio supporting the Company's novel cancer therapeutics London, UK, 27 May 2026 – Vidac Pharma Holdings Plc. (XETR

Vidac Pharma in Advanced Negotiations to Join Quest for Health and Expand into Strasbourg

Company evaluating strategic expansion into leading European life sciences and innovation ecosystem London, UK, 12 May 2026 – Vidac Pharma Holdings Plc. (XETRA:

Strategic Expansion into Continental Europe

London, UK, 21 April 2026 – Vidac Pharma Holdings Plc. (XETRA: T9G | ISIN: GB00BM9XQ619 | WKN: A3DTUQ) announces that it is evaluating a strategic expansion of

Financial Support by Main Shareholders and Directors of Vidac Pharma Holding PLC

London, UK, 11 March 2026 – Vidac Pharma Holdings Plc. (XETRA: T9G | ISIN: GB00BM9XQ619 | WKN: A3DTUQ) announces that in order to accelerate the development eff

Vidac Pharma Presents Compassionate Case in Pediatric Brain Cancer at the Eilat Symposium on Pediatric Cancer

London, UK, 3 March 2026 – Vidac Pharma Holdings Plc. (XETRA: T9G | ISIN: GB00BM9XQ619 | WKN: A3DTUQ) announces that the Company presented results from a compas

Vidac Pharma Holding PLC Announces Share Issuance, Employee Share Option Plan and Strategic Investment Authorisation

Vidac Pharma Holding PLC (the 'Company') is pleased to announce a series of corporate actions approved by its Board of Directors. Issuance of New Ordinary Share

Vidac Pharma Reports First Patient Dosed in Phase 2b Study of VDA-1102 for High-Risk Actinic Keratosis

London, UK, 23 February, 2026 – Vidac Pharma Holdings Plc. (XETRA: T9G | ISIN: GB00BM9XQ619 | WKN: A3DTUQ) announces that the first patient has been successfull

Vidac Pharma to Present Company Progress at the 19th Annual European Life Sciences CEO Forum Organized by Sachs Associates

London, UK, 16 February, 2026 – Vidac Pharma Holdings Plc. (XETRA: T9G | ISIN: GB00BM9XQ619 | WKN: A3DTUQ) announces that Dr. Max Herzberg, Chairman and Chief E

Vidac Pharma Holding Plc Initiates In Vivo Pre-Clinical Program in Psoriasis, Expanding Its HK2/VDAC Platform Beyond Oncology

Study to be conducted by PharmaLegacy, a leading Contract Research Organization London (UK) 11 February 2026 – Vidac Pharma Holding Plc (XETRA and Tradegate: T9

Vidac Pharma Receives Notice of Issuance from USPTO for One of Its Core Patents

London, UK, 12 January 2026 – Vidac Pharma Holdings Plc. (XETRA: T9G | ISIN: GB00BM9XQ619 | WKN: A3DTUQ) announces that it has received a Notice of Issuance fro

Vidac Pharma Holdings Plc Announces Commencement of Trading on Xetra

Trading on Frankfurt Deutsche Börse’s Xetra platform enhances Vidac Pharma’s visibility and access to European investors London, UK– December 15, 2025 – Vidac P

Vidac Pharma Holdings Plc Announces Initiation of Phase 2B* Clinical Trial for Targeted Treatment of Highly Proliferative Actinic Keratosis Lesions

_London, UK – 11 December 2025_ – Vidac Pharma Holdings Plc., (Dusseldorf, Hamburg and Stuttgart: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) a clinical-stage biophar

VIDAC PHARMA HOLDING PLC: Successful Listing in Düsseldorf Stock Exchange's Open Market, Primary Market Segment, and Results of Public Offering

PRESS RELEASEfromVIDAC PHARMA HOLDING PLCLondon, United Kingdom THE INFORMATION CONTAINED IN THIS DOCUMENT IS NOT FOR PUBLICATION OR DISTRIBUTION, IN WHOLE OR I

VIDAC PHARMA HOLDING PLC: Approval of Düsseldorf Stock Exchange: Inclusion in the Open Market, Primary Market Segment, and Public Offering Scheduled for 1 December 2025

PRESS RELEASE from VIDAC PHARMA HOLDING PLC London, United Kingdom THE INFORMATION CONTAINED IN THIS DOCUMENT IS NOT FOR PUBLICATION OR DISTRIBUTION, IN WHOLE O

Vidac Pharma Invited to Present at the 17th International Investment Forum (IIF) on December 3rd, 2025

London (UK), November 27th, 2025 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharma

Upcoming Inclusion in the Open Market of the Düsseldorf Stock Exchange, Primary Market Segment, and Public Offering

PRESS RELEASE from VIDAC PHARMA HOLDING PLC London, United Kingdom THE INFORMATION CONTAINED IN THIS DOCUMENT IS NOT FOR PUBLICATION OR DISTRIBUTION, IN WHOLE O

Vidac Pharma Receives Renewed “Buy” Rating from Sphene Capital Following German Authorization for New Phase 2 AK Trial

London (UK), November 21 st 2025 – _Vidac Pharma Holdings Plc._ (Hamburg and Stuttgart: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology company

Vidac Pharma is proud to announce Clinical Trial Approval in Germany following CTIS update

London (UK), November 4th, 2025 – _Vidac Pharma Holdings Plc._ (Hamburg and Stuttgart: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage biopharmaceutical

Vidac Pharma to Present Possible Cooperation with Johnson & Johnson Specialists at Basel Launch’s “Beyond the Needle” Event

London (UK), October 23, 2025 – _Vidac Pharma Holdings Plc._ (Hamburg and Stuttgart: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ), – Vidac Pharma Ltd., a clinical-stag

VIDAC PHARMA HOLDING PLC Plans Inclusion of Its Shares in the Open Market of the Düsseldorf Stock Exchange (Primary Market)

The planned inclusion aims to enhance share tradability and facilitate future access to XETRA trading. London (UK), October 21, 2025 – _Vidac Pharma Holdings Pl

Vidac Pharma Announces Broad U.S. Patent Claim Allowance for HK2-Detaching Compounds in Cancer Treatment

Notice of Allowance Covers Compounds, Compositions, and Methods for Treating HK2-Expressing Cancers London (UK), September 30 th , 2025 – Vidac Pharma Holdings

Vidac Pharma Submits Clinical Study Application to EMA for Advanced Actinic Keratosis Lesions

_Comprehensive dossier underscores rigorous scientific, clinical, and CMC preparation, with key support from CRO partners_ London (UK), 15 September 2025 – Vida

Sphene Equity Research Update Reaffirms “Buy” Rating on Vidac Pharma

_Continued analyst endorsement underscores confidence in shareholder value and growth potential_ London (UK), September 2025 – Vidac Pharma Holdings Plc. (Hambu

Vidac Pharma Holding Strengthens Leadership and Prepares for Accelerated Growth

Appointment of new CTO and planned stock exchange listing mark strategic steps toward the company’s next growth phase. London (UK) July 9th , 2025 – Vidac Pharm

Shareholders Letter and amended Proxy

Notice of Shareholders' meeting to be held on July 11th, 2024

NOTICE OF SHAREHOLDERS’ MEETING VIDAC PHARMA HOLDING PLC (the 'Company') Company Number: 13479728 Registered Office: 20-22, Wenlock Road, London, England, N1 7G

Vidac Pharma Receives “Buy” Rating and Increased Valuation from Sphene Capital, Underscoring Strong Growth Prospects

London (UK) June 25th , 2025 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), clinical-stage biopharmaceutical company

Vidac Pharma Announces Publication of New Peer-Reviewed Study Highlighting Breakthrough Anti-Cancer Mechanism of VDA1275

London (UK) June 10th, 2025– Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), Vidac Pharma, a clinical-stage biopharmace

Vidac Pharma Reports Exceptional Pharmacokinetics of Almavid™ Drug Candidate in Real-World Clinical study

_Revolutionary cancer treatment demonstrates potential for _ Almavid™ Drug Candidate_ application in solid tumors._ London (UK) May 28th, 2025– Vidac Pharma Ho

Vidac Pharma Launches “TME++” Pediatric Brain Tumor Research Consortium

London (UK) March 24th , 2025– Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), is a clinical-stage oncology biopharmace

Vidac Pharma Holding PLC Announces Participation in the First Pediatric Brain Tumor Research Meeting

London, UK – March 4, 2025 – Vidac Pharma Holding PLC (Hamburg and Stuttgart: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage biopharmaceutical company

Vidac Pharma Holding Plc to Conduct Investor Roadshow in Frankfurt and Munich, February 24–25, 2025

London (UK) February 20th, 2025 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), is a clinical-stage oncology biopharm

Vidac Pharma Selected to Present at the Prestigious Keiretsu Forum in Southern California on February 27, 2025

London (UK) February 17th, 2025 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), is a clinical-stage oncology biopharm

Vidac Pharma Invited to Sachs Annual European Life Sciences CEO Forum 2025 in Zürich

London (UK) February 10th, 2025 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), is a clinical-stage oncology biopharm

Vidac Pharma Announces Major Milestones as It Prepares for its next stage as a Clinical entity

London (UK) February 4th, 2025 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), is a clinical-stage oncology biopharma

Exceptional Life Extension and Tumor Reduction Achieved with Vidac Pharma Holdings Plc’s VDA1275 in Combination with Low-Dose Cis-Platinum in Colorectal Cancer Animal Model

London (UK) January 28th, 2025– Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), is a clinical-stage oncology biopharmac

Vidac Pharma Holding PLC Announces Dr. Max Herzberg’s Participation in Innovative Brain Cancer Meeting at Google Campus, Tel Aviv

London (UK) January 23rd , 2025 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), is a clinical-stage oncology biopharm

Vidac Pharma Receives Final Report on Cutaneous T-Cell Lymphoma (CTCL) Clinical Study, Paving the Way for Phase 2-3 Trials

Innovative VDA-1102 Ointment Demonstrates Rapid and PromisingEfficacy in Addressing Unmet needs in CTCL care London (UK) January 2 nd , 2025– Vidac Pharma Holdi

U.S. grants broader patent to Vidac Pharma’s oncology drug candidates, adding range of new indications including prostate and pancreatic cancer

S. patent office widens patent to include broad range of new cancer indications including prostate, pancreatic, lung, cervical and colon cancer Vidac on track

Vidac Pharma receives reinvestment from shareholders to drive clinical trials of its cancer drug candidates

• Strong engagement: more than 90% of owners participated in the Annual Shareholder Meeting where capital raise was announced, showing solid commitment to Vidac

VIDAC PHARMA HOLDING PLC held its Annual General Meeting (AGM) of 2024

London (UK), October 30 2024 (11:00 CET) – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology bi

Notice to shareholders Annual general meeting to be held on Wednesday 30 October 2024

THIS PUBLICATION IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to any aspect of the proposals referred to in this publication o

Proxy appointment

Proxy appointment For the purposes of voting on the Annual General Meeting of shareholders of VIDAC PHARMA HOLDING PLC (Name of the shareholder) (Address of the

U.S. grants Vidac Pharma patent offering broad protection of mode of action underlying its oncology drug candidates

London (UK), September 19 2024 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceu

Vidac Pharma publishes results of next-generation drug candidate tests in human and murine tumor models

London (UK), July 25, 2024 (07:30 CET) – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biop

Vidac Pharma receives US patent office Notice of Allowance for crucial compounds in its cancer drug candidates

London (UK), June 3, 2024 (07:30 CET) – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology bioph

Vidac Pharma advances cancer metabolism inhibitor VDA-1275 into preclinical IND-enabling studies

London (UK), April 29, 2024 (07:30 CET) – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology bio

Vidac Pharma receives Japanese Patent Office Notice of Allowance for VDA-1275 cancer drug candidate

London (UK), March 27, 2024 (07:30 CET) – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology bio

Vidac Pharma secures approval for next phase of clinical study into lead asset into CTCL

London (UK), March 11, 2024 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutic

Vidac Pharma presents high efficacy in multiple solid tumor models for its next-generation cancer drug candidate and synergy with standard-of-care treatment in liver cancer organoids

London (UK), February 19, 2024, 7:30 am CET – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology

Vidac Pharma to present company at Sachs European Healthtech CEO Forum with latest developments of revolutionary approach to treat cancer

London (UK), February 12, 2024 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceu

Vidac Pharma receives issue notification from US patent office for manufacturing of lead asset VDA-1102

London ( UK), February 6, 2024 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceu

Vidac Pharma reports favorable data from Phase 2a interim analysis for its lead asset VDA-1102 in CTCL

London (UK), January 29, 2024 – – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmace

Vidac Pharma sees growing recognition of its innovative approach to fight cancer

London (UK), January 22, 2024 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceut

Vidac Pharma to present strategy and upcoming milestones to leading investors in Switzerland in January

London (UK), January 15, 2024 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceut

Vidac Pharma to conduct Phase 2b study for actinic keratosis therapeutic candidate VDA-1102 at CentroDerm

London (UK), Rehovot (Israel), December 19th 2023 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage on

Vidac Pharma reports in vitro results showing VDA-1275 compatible with classical chemotherapy and  Novel cancer cell metabolism regulator to progress into IND enabling studies

London (UK), Rehovot (Israel), 29 November 2023– Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncol

Vidac Pharma is happy to inform that it received an official Notice of Allowance from the US Patent Office (USPTO)

Vidac Pharma is happy to inform that it received an official Notice of Allowance from the US Patent Office (USPTO) for its new Patent on a new Chemical synthesi

Vidac Pharma Holding Plc is happy to announce Granting of a new Patent in China

London (UK), Rehovot (IL), October 26th, 2023 Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). www.vidacpharma.com Vidac Pharma Holding P

Vidac Pharma Ltd receives “Seal of Excellence” from the European Commission Horizon Program

London (UK), Rehovot (IL), October 23rd, 2023 Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). www.vidacpharma.com Vidac Pharma Holding P

Vidac Pharma Ltd announce impressive solidarity from its shareholders, employees and collaborators

London (UK), Rehovot (IL), October 17th, 2023 Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). www.vidacpharma.com Vidac Pharma Ltd, the

Vidac Pharma Holding Plc is happy to announce that it held its Annual Shareholder Meeting on Friday 29/9/23

London (UK), Rehovot (IL), October 2nd, 2023 Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). www.vidacpharma.com More than 80% of the Sh

Vidac Pharma Holding Plc to hold Annual Shareholders Meeting Sept 29th, 2023

London (UK), Rehovot (IL), 13th September 2023 Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). www.vidacpharma.com Vidac Pharma Holding

Vidac Pharma announces international experts’ participation to its “Toposteric” Round Table at HTID5 in Paris Oct 24-25, 2023

London (UK), Rehovot (IL), Paris (FR) August 30h, 2023 Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). www.vidacpharma.com Under the Org

Vidac Pharma announces signature of a Research Collaboration and License Agreement with Sheba Hospital Tel Hashomer

London (UK), Rehovot (Israel) Tel Hashomer (Israel) August, 2023 Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). www.vidacpharma.com Vid

Vidac Pharma Holding cooperation with Centroderm Gmbh for its next Clinical Trial in Actinic Keratosis

London (UK), Rehovot (Israel) Wuppertal (Germany) August 15th, 2023 Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). www.vidacpharma.com

Vidac Pharma Holding Plc. to be in a dual listing in Hamburg and Stuttgart stock Exchanges.

London (UK), Rehovot (Israel) August 11th, 2023 Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). www.vidacpharma.com London August 11. Vi

VIDAC PHARMA HOLDING Plc Shareholder Unanimous Vote for Capital Increase delegated to its Board

London (UK), Rehovot (Israel) August 10th, 2023 Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). www.vidacpharma.com London UK. The extra

Vidac Pharma to hold Extraordinary Shareholder Meeting to prepare for potential investments

London (UK), Rehovot (Israel) July 26th, 2023 Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). www.vidacpharma.com Vidac Pharma to hold E

Vidac Pharma and HCS Pharma Announce cooperative agreement on acceleration of pre-clinical assays for Vidac Pharma anti Solid Tumors drug candidates

London (UK), Rehovot (Israel) Lille (France) July 17th , 2023 Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). www.vidacpharma.com Poor p

Vidac Pharma invited to organize Round Table on its Toposteric Paradigm at main European Health Tech Conference

Vidac Pharma invited to organize Round Table on its Toposteric Paradigm at main European Health Tech Conference London (UK) and Rehovot (Israel) July 10th, 2023

Vidac Pharma invited to organize Round Table on its Toposteric Paradigm at main European Health Tech Conference

London (UK) and Rehovot (Israel) July 5th, 2023 Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). www.vidacpharma.com Vidac Pharma was inv

Vidac Pharma announces positive preliminary results of its Phase 2A in CTCL

London (UK) and Rehovot (Israel) June 27th, 2023 Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). www.vidacpharma.com The preliminary res

Vidac Pharma will participate to the HTID5 as a fully sponsored guest speak

London (UK) and Rehovot (Israel) June 16th, 2023 Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). (www.vidacpharma.com) As one of three l

Vidac Pharma Holding Plc. Nomination of new Board and Scientific Advisory committee and update.

London (UK) and Rehovot (Israel) April 26, 2023 Vidac Pharma Holding Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). (www.vidacpharma.com) In preparation for

Expiration of the G.E.M Share Purchase Facility

London (UK) and Rehovot (Israel) April 24, 2023 Vidac Pharma Holding Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). (www.vidacpharma.com) Vidac Pharma Holdin

VIDAC PHARMA HOLDING PLC SHARES ARE ADMITTED FOR TRADING BY HAMBURG STOCK EXCHANGE

London (UK) and Rehovot (Israel). VIDAC PHARMA HOLDING PLC (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). (www.vidacpharma.com) is happy to announce a listing of

VIDAC PHARMA LTD ANNOUNCES WIDER SPECTRUM AUTHORIZATION OF ITS CTCL PHASE 2 CLINICAL TRIAL.

Rehovot, Israel Sept 20, 2021 Based of the satisfactory safety data of VIDAC VDA 1102 on selected patients, Vidac Pharma received authorization to widen the sco

Vidac Pharma Ltd.: New Chemical Entities Patent Granted

Rehovot, Israel Sept 13, 2021 Vidac Pharma Ltd. announces that it was granted a USA Patent for a new chemical family of compounds targeting the HK2-VDAC system

Vidac Pharma Secures EUR 20m Capital Commitment From GEM

NESS-ZIONA, Israel, April 19, 2021 /PRNewswire/ -- Vidac Pharma LTD (Vidac) a clinical-stage Israel biopharmaceutical company, announced today that it has signe

VIDAC PHARMA ANNOUNCES INCLUSION OF THE FIRST PATIENT IN A PLACEBO CONTROLLED PHASE II STUDY

Jerusalem, Israel, February 09 2021 – Vidac Pharma Ltd announces inclusion of the first Patient in a Placebo controlled Phase II study in early forms of Cutaneo

VIDAC PHARMA ANNOUNCES PUBLICATION OF A PEER REVIEWED ARTICLE ON VDA-1102 MECHANISM OF ACTION

Jerusalem, Israel, December 16 2018 – Vidac Pharma, a clinical stage oncology and dermatology focused pharmaceutical company, announce the publication of its la

VIDAC PHARMA TO PRESENT A POSTER AT THE SITC 2018 MEETING

Jerusalem, Israel, November 4, 2018 – Vidac Pharma, a clinical stage oncology-focused immune-metabolism company, today announced that it will present a poster a

VIDAC PHARMA ANNOUNCES INITIATION OF PHASE 2B CLINICAL TRIAL OF VDA-1102 OINTMENT IN PATIENTS WITH ACTINIC KERATOSIS

Jerusalem, Israel, July 10 2018 – Vidac Pharma, a clinical stage oncology and dermatology focused pharmaceutical company, today announced initiation of a Phase

VIDAC PHARMA TO PRESENT A POSTER AT THE EACR25 2018 MEETING

Jerusalem, Israel, June 20, 2018 – Vidac Pharma, a clinical stage oncology-focused immune-metabolism company, today announced that it will present a poster enti

VIDAC PHARMA TO PRESENT AN IMMUNO-METABOLISM POSTER AT THE 2018 AACR ANNUAL MEETING 2018

Jerusalem, Israel, April 4, 2018 – Vidac Pharma, a clinical stage oncology and dermatology-focused biopharmaceutical company, today announced that it will prese

VIDAC PHARMA TO PRESENT AT THE 2018 BIO CEO & INVESTOR CONFERENCE

Jerusalem, Israel, January 23, 2018 – Vidac Pharma, a clinical-stage oncology and dermatology-focused biopharmaceutical company, today announced that Oren M. Be

VIDAC PHARMA TO PRESENT AT THE 2018 4TH ANNUAL DERMATOLOGY INNOVATION FORUM

Jerusalem, Israel, December 6, 2017 – Vidac Pharma, a clinical stage oncology and dermatology-focused biopharmaceutical company, today announced that it will pa

VIDAC PHARMA REPORTS POSITIVE RESULTS FROM PHASE 2A PROOF-OF-CONCEPT TRIAL OF VDA-1102 OINTMENT IN ACTINIC KERATOSIS

Vidac Pharma reports positive results from Phase 2A Proof-of-concept trial of VDA-1102 OINTMENTin Actinic Keratosis Establishes that VDA-1102 ointment is well-t

VIDAC PHARMA APPOINTS CHIEF MEDICAL AND CHIEF SCIENCE OFFICERS

Jerusalem, Israel, January 1, 2017 - Vidac Pharma, a clinical-stage oncology-focused pharmaceutical company, today announced the appointment of Dr. Chaim Brickm

VIDAC PHARMA PHASE 2A STUDY OF VDA-1102 IN ACTINIC KERATOSIS MEETS INTERIM ANALYSIS CRITERION

Jerusalem, Israel, December 12, 2016 – Vidac Pharma, a clinical-stage oncology-focused pharmaceutical company, today announced that the ongoing Phase 2 study wi

VIDAC PHARMA ANNOUNCES THE INNITIATION OF A PHASE 2A STUDY OF VDA-1102 OINTMENT IN PATIENTS WITH ACTINIC KERATOSIS

Jerusalem, Israel, July 29, 2016 – Vidac Pharma, a clinical stage oncology focused pharmaceutical company, today announced that the Company has initiated a Phas

VIDAC PHARMA COMPLETES PHASE 1A TRIAL OF VDA-1102 OINTMENT

Jerusalem, Israel, June 30, 2016 - Vidac Pharma, a clinical stage oncology focused pharmaceutical company, today announced that the Company has completed a Phas

Vidac Pharma Completes $9 Million Series A Financing I Advances Phase 2 Studies with VDA-1102 In Actinic Keratosis

Jerusalem, Israel, June 29, 2016 - Vidac Pharma, a privately-held clinical stage pharmaceutical company developing novel small molecule therapeutics for the tre

Vidac Pharma Initiates Phase I Clinical Trial With Its Novel VDAC/HK2 Modulator

Jerusalem, Israel, February 25, 2016 - Vidac Pharma, a clinical stage drug development company, today announced the initiation of Phase I first-in-human studies

Vidac Pharma Announces Filing of IND with U.S. FDA for Development of VDA-1102 for Treatment of Actinic Keratosis

Jerusalem, Israel, December 30, 2015 – Vidac Pharma, a drug discovery and development company, today announced the filing of an Investigational New Drug (IND) a

Vidac Pharma Appoints Dr. Chaim Brickman as Vice President of Clinical Affairs

Jerusalem, Israel, November 15, 2014 - Vidac Pharma, a drug discovery and development company, today announced the appointment of Chaim M. Brickman, M.D. as its

Vidac Pharma Appoints Dr. Paul Salama as Vice President of Chemistry, Manufacturing, and Control

Ness Ziona, Israel, August 19, 2014 - Vidac Pharma, a drug discovery and development company, today announced the appointment of Dr. Paul Salama as its vice pre